US Bancorp
CTMX icon

US Bancorp’s CytomX Therapeutics CTMX Stock Holding History

US Bancorp’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-7,392
Closed -$4.7K – 4190
2025
Q1 		$4.7K Sell
7,392
-23,400
-76% -$18.1K ﹤0.01% 3678
2024
Q4 		$31.7K Sell
30,792
-3,000
-9% -$3.23K ﹤0.01% 2955
2024
Q3 		$39.9K Buy
+33,792
New +$42.9K ﹤0.01% 2848
2022
Q1 		– Sell
-50
Closed – – 4079
2021
Q4 		$0 Buy
+50
New +$293 ﹤0.01% 4113
2020
Q3 		– Sell
-309
Closed -$3K – 3726
2020
Q2 		$3K Buy
309
+105
+51% +$975 ﹤0.01% 3421
2020
Q1 		$2K Hold
204
– – ﹤0.01% 3445
2019
Q4 		$2K Buy
+204
New +$1.38K ﹤0.01% 3462

Other funds holding CTMX

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

US Bancorp's CTMX Position: Q2 2025 in Review

US Bancorp sold out of CytomX Therapeutics (CTMX) in Q2 2025, closing a stake of 7,392 shares — an estimated $4.7K sold.

US Bancorp first reported a position in CTMX in Q4 2019 and held it in 7 quarters. The position peaked at $39.9K in Q3 2024. 83 funds tracked by Wall St. Rank hold CTMX as of Q2 2025.

  • US Bancorp reported no remaining CytomX Therapeutics position as of Q2 2025 after selling out during the quarter.
  • US Bancorp sold 7,392 CytomX Therapeutics shares in Q2 2025, an estimated $4.7K.
  • US Bancorp first reported a position in CytomX Therapeutics in Q4 2019 and held it in 7 quarters.
  • US Bancorp's CytomX Therapeutics position peaked at $39.9K in Q3 2024.
  • 83 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2025.

Based on US Bancorp's 13F filing for Q2 2025, filed 24 Jul 2025.